These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 12372616)

  • 1. Study of the cytotoxic effect of a peptidic inhibitor of the p53-hdm2 interaction in tumor cells.
    Chène P; Fuchs J; Carena I; Furet P; García-Echeverría C
    FEBS Lett; 2002 Oct; 529(2-3):293-7. PubMed ID: 12372616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines.
    Chène P; Fuchs J; Bohn J; García-Echeverría C; Furet P; Fabbro D
    J Mol Biol; 2000 May; 299(1):245-53. PubMed ID: 10860736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic effect of a non-peptidic small molecular inhibitor of the p53-HDM2 interaction on tumor cells.
    Li WD; Wang MJ; Ding F; Yin DL; Liu ZH
    World J Gastroenterol; 2005 May; 11(19):2927-31. PubMed ID: 15902730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. UV-radiation induces dose-dependent regulation of p53 response and modulates p53-HDM2 interaction in human fibroblasts.
    Latonen L; Taya Y; Laiho M
    Oncogene; 2001 Oct; 20(46):6784-93. PubMed ID: 11709713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure.
    Zhao J; Wang M; Chen J; Luo A; Wang X; Wu M; Yin D; Liu Z
    Cancer Lett; 2002 Sep; 183(1):69-77. PubMed ID: 12049816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abundant expression of spliced HDM2 in Hodgkin lymphoma cells does not interfere with p14(ARF) and p53 binding.
    Stürzenhofecker B; Schlott T; Quentin T; Kube D; Jung W; Trümper L
    Leuk Lymphoma; 2003 Sep; 44(9):1587-96. PubMed ID: 14565663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
    Lau LM; Nugent JK; Zhao X; Irwin MS
    Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular characterization of the hdm2-p53 interaction.
    Böttger A; Böttger V; Garcia-Echeverria C; Chène P; Hochkeppel HK; Sampson W; Ang K; Howard SF; Picksley SM; Lane DP
    J Mol Biol; 1997 Jun; 269(5):744-56. PubMed ID: 9223638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs.
    Laín S; Midgley C; Sparks A; Lane EB; Lane DP
    Exp Cell Res; 1999 May; 248(2):457-72. PubMed ID: 10222137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells.
    Yang Y; Ludwig RL; Jensen JP; Pierre SA; Medaglia MV; Davydov IV; Safiran YJ; Oberoi P; Kenten JH; Phillips AC; Weissman AM; Vousden KH
    Cancer Cell; 2005 Jun; 7(6):547-59. PubMed ID: 15950904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells.
    Phelps M; Darley M; Primrose JN; Blaydes JP
    Cancer Res; 2003 May; 63(10):2616-23. PubMed ID: 12750288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation.
    Kurki S; Peltonen K; Latonen L; Kiviharju TM; Ojala PM; Meek D; Laiho M
    Cancer Cell; 2004 May; 5(5):465-75. PubMed ID: 15144954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mdm2 inhibition of p53 induces E2F1 transactivation via p21.
    Wunderlich M; Berberich SJ
    Oncogene; 2002 Jun; 21(28):4414-21. PubMed ID: 12080472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1,4-Benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53 interaction: discovery and SAR.
    Parks DJ; Lafrance LV; Calvo RR; Milkiewicz KL; Gupta V; Lattanze J; Ramachandren K; Carver TE; Petrella EC; Cummings MD; Maguire D; Grasberger BL; Lu T
    Bioorg Med Chem Lett; 2005 Feb; 15(3):765-70. PubMed ID: 15664854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Helical beta-peptide inhibitors of the p53-hDM2 interaction.
    Kritzer JA; Lear JD; Hodsdon ME; Schepartz A
    J Am Chem Soc; 2004 Aug; 126(31):9468-9. PubMed ID: 15291512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma.
    Mori S; Ito G; Usami N; Yoshioka H; Ueda Y; Kodama Y; Takahashi M; Fong KM; Shimokata K; Sekido Y
    Cancer; 2004 Apr; 100(8):1673-82. PubMed ID: 15073856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CARF (collaborator of ARF) interacts with HDM2: evidence for a novel regulatory feedback regulation of CARF-p53-HDM2-p21WAF1 pathway.
    Hasan MK; Yaguchi T; Harada JI; Hirano T; Wadhwa R; Kaul SC
    Int J Oncol; 2008 Mar; 32(3):663-71. PubMed ID: 18292944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a binding assay for p53/HDM2 by using homogeneous time-resolved fluorescence.
    Kane SA; Fleener CA; Zhang YS; Davis LJ; Musselman AL; Huang PS
    Anal Biochem; 2000 Feb; 278(1):29-38. PubMed ID: 10640350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ligand-dependent interaction of the glucocorticoid receptor with p53 enhances their degradation by Hdm2.
    Sengupta S; Wasylyk B
    Genes Dev; 2001 Sep; 15(18):2367-80. PubMed ID: 11562347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-peptides with improved affinity for hDM2 and hDMX.
    Harker EA; Daniels DS; Guarracino DA; Schepartz A
    Bioorg Med Chem; 2009 Mar; 17(5):2038-46. PubMed ID: 19211253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.